Top

Gepubliceerd in:

01-04-2011

Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence

Auteurs: Christina S. Meade, Nina A. Conn, Linda M. Skalski, Steven A. Safren

Gepubliceerd in: Journal of Behavioral Medicine | Uitgave 2/2011

Abstract

Cocaine abuse among HIV patients is associated with faster disease progression and mortality. This study examined the relationship between neurocognitive functioning and medication adherence in HIV patients with (n = 25) and without (n = 39) current cocaine dependence. Active users had greater neurocognitive impairment (mean T-score = 35.16 vs. 40.97, p < .05) and worse medication adherence (mean z-score = −0.44 vs. 0.27, p < .001). In a multiple regression model, neurocognitive functioning (β = .33, p < .01) and cocaine dependence (β = −.36, p < .01) were predictive of poorer adherence. There was a significant indirect effect of cocaine dependence on medication adherence through neurocognitive impairment (estimate = −0.15, p < .05), suggesting that neurocognitive impairment partially mediated the relationship between cocaine dependence and poorer adherence. These results confirm that cocaine users are at high risk for poor HIV outcomes and underscore the importance of treating both neurocognitive impairment and cocaine dependence among HIV patients.

vorige artikel Religious coping and hospital admissions among adults with sickle cell disease

volgende artikel Concept priming and pain: an experimental approach to understanding gender roles in sex-related pain differences

Aharonovich, E., Hasin, D. S., Brooks, A. C., Liu, X., Bisaga, A., & Nunes, E. V. (2006). Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug and Alcohol Dependence, 81(3), 313–322.PubMedCrossRef

Aharonovich, E., Nunes, E., & Hasin, D. (2003). Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug and Alcohol Dependence, 71(2), 207–211.PubMedCrossRef

Albert, S. M., Flater, S. R., Clouse, R., Todak, G., Stern, Y., & Marder, K. (2003). Medication management skill in HIV: I. Evidence for adaptation of medication management strategies in people with cognitive impairment. II. Evidence for a pervasive lay model of medication efficacy. AIDS and Behavior, 7(3), 329–338.PubMedCrossRef

Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394–402.PubMedCrossRef

Anthony, I. C., & Bell, J. E. (2008). The neuropathology of HIV/AIDS. International Review of Psychiatry, 20(1), 15–24.PubMedCrossRef

Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., et al. (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 69(18), 1789–1799.PubMedCrossRef

Applebaum, A. J., Otto, M. W., Richardson, M. A., & Safren, S. A. (2009). Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. Journal of Clinical and Experimental Neuropsychology, Epub ahead of print (Nov 4), 1–11.

Applebaum, A. J., Reilly, L. C., Gonzalez, J. S., Richardson, M. A., Leveroni, C. L., & Safren, S. A. (2009b). The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care and STDS, 23(6), 455–462.PubMedCrossRef

Ardila, A., Rosselli, M., & Strumwasser, S. (1991). Neuropsychological deficits in chronic cocaine abusers. International Journal of Neuroscience, 57(1–2), 73–79.PubMedCrossRef

Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegran, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17(5), 377–381.PubMed

Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. American Journal of Addictions, 10(1), 36–78.

Bangsberg, D. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43(7), 939941.CrossRef

Barclay, T. R., Hinkin, C. H., Castellon, S. A., Mason, K. I., Reinhard, M. J., Marion, S. D., et al. (2007). Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status. Health Psychology, 26(1), 40–49.PubMedCrossRef

Baron, R. M., & Kenny, D. A. (1996). The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology, 51(6), 1173–1182.CrossRef

Baum, M. K., Rafie, C., Lai, S., Sales, S., Page, B., & Campa, A. (2009). Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. Journal of Acquired Immune Deficiency Syndrome, 50(1), 93–99.CrossRef

Beatty, W. W., Katzung, V. M., Moreland, V. J., & Nixon, S. J. (1995). Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug and Alcohol Dependence, 37(3), 247–253.PubMedCrossRef

Benedict, R. H., Mezhir, J. J., Walsh, K., & Hewitt, R. G. (2000). Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life. Archives of Clinical Neuropsychology, 15(6), 535–544.PubMed

Benton, A., Hamsher, K., & Sivan, A. (1983). Multilingual aphasia examination (3rd ed.). Iowa City, IA: AJA Associates.

Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S., et al. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry, 58(8), 721–728.PubMedCrossRef

Bolla, K. I., Rothman, R., & Cadet, J. L. (1999). Dose-related neurobehavioral effects of chronic cocaine use. Journal of Neuropsychiatry and Clinical Neurosciences, 11(3), 361–369.PubMed

Brandt, J., & Benedict, R. H. B. (2001). Hopkins verbal learning test–Revised professional manual. Lutz, FL: Psychological Assessment Resources, Inc.

Brew, B. J., & Gonzalez-Scarano, F. (2007). HIV-associated dementia: An inconvenient truth. Neurology, 68(5), 324–325.PubMedCrossRef

Brew, B. J., Halman, M., Catalan, J., Sacktor, N., Price, R. W., Brown, S., et al. (2007). Factors in AIDS dementia complex trial designs: Results and lessons from the abacavir trial. PLoS Clinical Trials, 2(3), 13.CrossRef

Chander, G., Josephs, J., Fleishman, J. A., Korthuis, P. T., Gaist, P., Hellinger, J., et al. (2008). Alcohol use among HIV-infected persons in care: Results of a multi-site survey. HIV Medicine, 9(4), 196–202.PubMedCrossRef

Chang, L., Wang, G. J., Volkow, N. D., Ernst, T., Telang, F., Logan, J., et al. (2008). Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage, 42(2), 869–878.PubMedCrossRef

Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care, 12(3), 255–266.PubMedCrossRef

Clarke, S., Delamere, S., McCullough, L., Hopkins, S., Bergin, C., & Mulcahy, F. (2003). Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Medicine, 4(1), 33–37.PubMedCrossRef

Clifford, D. B., McArthur, J. C., Schifitto, G., Kieburtz, K., McDermott, M. P., Letendre, S., et al. (2002). A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology, 59(10), 1568–1573.PubMed

Cook, J. A., Grey, D. D., Burke-Miller, J. K., Cohen, M. H., Vlahov, D., Kapadia, F., et al. (2007). Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug and Alcohol Dependence, 89(1), 74–81.PubMedCrossRef

Dawes, S., Suarez, P., Casey, C. Y., Cherner, M., Marcotte, T. D., Letendre, S., et al. (2008). Variable patterns of neuropsychological performance in HIV-1 infection. Journal of Experimental and Clinical Neuropsychology, 30(6), 613–626.CrossRef

Durvasula, R. S., Myers, H. F., Satz, P., Miller, E. N., Morgenstern, H., Richardson, M. A., et al. (2000). HIV-1, cocaine, and neuropsychological performance in African American men. Journal of the International Neuropsychological Society, 6(3), 322–335.PubMedCrossRef

Efron, B., & Tibshirani, R. J. (1993). An introduction to the bootstrap. Boca Raton, FL: Chapman & Hall.

Fals-Stewart, W., & Lucente, S. (1994). Effect of neurocognitive status and personality functioning on length of stay in residential substance abuse treatment: An integrative study. Psychology of Addictive Behaviors, 8(3), 179–190.CrossRef

First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1996). Structured clinical interview for DSM-IV axis I disorders, research version, Patient/Non-patient Edition, (SCID-I/P) or (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute.

Fletcher, C. V., Testa, M. A., Brundage, R. C., Chesney, M. A., Haubrich, R., Acosta, E. P., et al. (2005). Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. Journal of Acquired Immune Deficiency Syndrome, 40(3), 301–306.CrossRef

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.PubMedCrossRef

Fox, H. C., Jackson, E. D., & Sinha, R. (2009). Elevated cortisol and learning and memory deficits in cocaine dependent individuals: Relationship to relapse outcomes. Psychoneuroendocrinology, 34(8), 1198–1207.PubMedCrossRef

Giordano, T. P., Guzman, D., Clark, R., Charlebois, E. D., & Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clinical Trials, 5(2), 74–79.PubMedCrossRef

Heaton, R. K., Grant, I., Butters, N., White, D. A., Kirson, D., Atkinson, J. H., et al. (1995). The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. Journal of the International Neuropsychological Society, 1(3), 231–251.PubMedCrossRef

Heaton, R. K., Marcotte, T. D., Mindt, M. R., Sadek, J., Moore, D. J., Bentley, H., et al. (2004a). The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society, 10(3), 317–331.PubMedCrossRef

Heaton, R. K., Miller, S. W., Taylor, M. J., & Grant, I. (2004b). Revised comprehensive norms for an expanded halstead-reitan battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz, FL: Psychological Assessment Resources, Inc.

Hinkin, C. H., Barclay, T. R., Castellon, S. A., Levine, A. J., Durvasula, R. S., Marion, S. D., et al. (2007). Drug use and medication adherence among HIV-1 infected individuals. AIDS and Behavior, 11(2), 185–194.PubMedCrossRef

Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., Mason, K. I., et al. (2002). Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology, 59(12), 1944–1950.PubMed

Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., et al. (2004). Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS, 18(Supp 1), 19–25.

Hoff, A. L., Riordan, H., Morris, L., Cestaro, V., Wieneke, M., Alpert, R., et al. (1996). Effects of crack cocaine on neurocognitive function. Psychiatry Research, 60(2–3), 167–176.PubMedCrossRef

Hult, B., Chana, G., Masliah, E., & Everall, I. (2008). Neurobiology of HIV. International Review of Psychiatry, 20(1), 3–13.PubMedCrossRef

Kalichman, S. C., Amaral, C. M., Swetzes, C., Jones, M., Macy, R., Kalichman, M. O., et al. (2009). A simple single-item rating scale to measure medication adherence: Further evidence for convergent validity. Journal of the International Association of Physicians in AIDS Care, 8(6), 367–374.PubMedCrossRef

Korthuis, P. T., Zephyrin, L. C., Fleishman, J. A., Saha, S., Josephs, J. S., McGrath, M. M., et al. (2008). Health-related quality of life in HIV-infected patients: The role of substance use. AIDS Patient Care and STDS, 22(11), 859–867.PubMedCrossRef

Kuo, W. H., Wilson, T. E., Weber, K. M., Madhava, V., Richardson, J., Delapenha, R., et al. (2004). Initiation of regular marijuana use among a cohort of women infected with or at risk for HIV in the Women’s Interagency HIV Study (WIHS). AIDS Patient Care and STDS, 18(12), 702–713.PubMedCrossRef

Levine, A. J., Hardy, D. J., Miller, E., Castellon, S. A., Longshore, D., & Hinkin, C. H. (2004). The effect of recent stimulant use on sustained attention in HIV-infected adults. Journal of Clinical and Experimental Neuropsychology, 28(1), 29–42.CrossRef

Levine, A. J., Hinkin, C. H., Castellon, S. A., Mason, K. I., Lam, M. N., Perkins, A., et al. (2005). Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS and Behavior, 9(3), 355–362.PubMedCrossRef

Lezac, M. D. (1995). Neuropsychological assessment (3rd ed.). New York: Oxford University Press.

Liu, H., Miller, L. G., Golin, C. E., Wu, T., Wenger, N. S., & Kaplan, A. H. (2006). Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. Journal of Acquired Immune Deficiency Syndrome, 41(3), 315–322.CrossRef

London, E. D., Bonson, K. R., Ernst, M., & Grant, S. (1999). Brain imaging studies of cocaine abuse: Implications for medication development. Critical Reviews in Neurobiology, 13(3), 227–242.PubMed

Lovejoy, T. I., & Suhr, J. A. (2009). The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: A systematic review. Journal of Behav Medicine, 32(5), 389–405.CrossRef

Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., et al. (2008). Optimal recall period and response task for self-reported HIV medication adherence. AIDS and Behavior, 12(1), 86–94.PubMedCrossRef

Mackinnon, D. P., Lockwood, C. M., & Williams, J. (2004). Confidence limits for the indirect effect: Distribution of the product and resampling methods. Multivariate Behavioral Research, 39(1), 99.PubMedCrossRef

McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., et al. (1992). The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment, 9(3), 199–213.PubMedCrossRef

Medina, K. L., Shear, P. K., & Schafer, J. (2006). Memory functioning in polysubstance dependent women. Drug and Alcohol Dependence, 84(3), 248–255.PubMedCrossRef

Meyers, J. E., & Meyers, K. R. (1995). Rey complex figure test and recognition trial. Lutz, FL: Psychological Assessment Resources, Inc.

Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006). Adherence to antiretroviral therapy in sub-Saharan African and North American. JAMA, 296(6), 679–690.PubMedCrossRef

Monterosso, J. R., Ainslie, G., Xu, J., Cordova, X., Domier, C. P., & London, E. D. (2007). Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task. Human Brain Mapping, 28(5), 383–393.PubMedCrossRef

Moore, D. J., Masliah, E., Rippeth, J. D., Gonzalez, R., Carey, C. L., Cherner, M., et al. (2006). Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS, 20(6), 879–887.PubMedCrossRef

Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., & Samet, J. H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99(3), 361–368.PubMedCrossRef

Paulus, M. P., Hozack, N. E., Zauscher, B. E., Frank, L., Brown, G. G., Braff, D. L., et al. (2002). Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology, 26(1), 53–63.PubMedCrossRef

Preacher, K. J., & Hayes, A. F. (2004). SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behavioral Research Methods, Instruments, and Computers, 36(4), 717–731.CrossRef

Rabkin, J. G., McElhiney, M., Ferrando, S. J., Van Gorp, W., & Lin, S. H. (2004). Predictors of employment of men with HIV/AIDS: A longitudinal study. Psychosomatic Medicine, 66(1), 72–78.PubMedCrossRef

Reback, C. J., Larkins, S., & Shoptaw, S. (2003). Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care, 15(6), 775–785.PubMedCrossRef

Reger, M., Welsh, R., Razani, J., Martin, D. J., & Boone, K. B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society, 8(3), 410–424.PubMedCrossRef

Reynolds, N. R., Sun, J., Nagaraja, H. N., Gifford, A. L., Wu, A. W., & Chesney, M. A. (2007). Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: A cross-protocol analysis. Journal of Acquired Immune Deficiency Syndromes, 46(4), 402–409.PubMedCrossRef

Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., Gonzalez, R., et al. (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 10(1), 1–14.PubMedCrossRef

Rosselli, M., Ardila, A., Lubomski, M., Murray, S., & King, K. (2001). Personality profile and neuropsychological test performance in chronic cocaine-abusers. International Journal of Neuroscience, 110(1–2), 55–72.PubMedCrossRef

Roux, P., Carrieri, M. P., Villes, V., Dellamonica, P., Poizot-Martin, I., Ravaux, I., et al. (2008). The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction, 103(11), 1828–1836.PubMedCrossRef

Sacktor, N. (2002). The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Journal of Neurovirology, 8(Suppl 2), 115–121.PubMedCrossRef

Schifitto, G., Navia, B. A., Yiannoutsos, C. T., Marra, C. M., Chang, L., Ernst, T., et al. (2007). Memantine and HIV-associated cognitive impairment: A neuropsychological and proton magnetic resonance spectroscopy study. AIDS, 21(14), 1877–1886.PubMedCrossRef

Schrimsher, G., & Parker, J. (2008). Changes in cognitive function during substance use disorder treatment. Journal of Psychopathology and Behavioral Assessment, 30(2), 146–153.CrossRef

Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl 30), 22–33.PubMed

Shuter, J., Sarlo, J. A., Kanmaz, T. J., Rode, R. A., & Zingman, B. S. (2007). HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. Journal of Acquired Immune Deficiency Syndrome, 45(1), 4–8.CrossRef

Simon, S. L., Domier, C., Carnell, J., Brethen, P., Rawson, R., & Ling, W. (2000). Cognitive impairment in individuals currently using methamphetamine. American Journal on Addictions, 9(3), 222–231.PubMedCrossRef

Smith, A. (1973). Symbol digit modalities test (SDMT). San Antonio: The Psych Corp.

Smith, A. (2007). Symbol digit modalities test manual. Los Angeles, CA: Western Psychological Services.

Sobell, L. C., & Sobell, M. B. (1996). Timeline follow back: A calendar method for assessing alcohol and drug use. Toronto, Canada: Addiction Research Foundation.

Solomon, T. M., & Halkitis, P. N. (2008). Cognitive executive functioning in relation to HIV medication adherence among gay, bisexual, and other men who have sex with men. AIDS and Behavior, 12(1), 68–77.PubMedCrossRef

Teichner, G., Horner, M. D., & Harvey, R. T. (2001). Neuropsychological predictors of the attainment of treatment objectives in substance abuse patients. International Journal of Neuroscience, 106(3/4), 253.PubMedCrossRef

Toomey, R., Lyons, M. J., Eisen, S. A., Xian, H., Chantarujikapong, S., Seidman, L. J., et al. (2003). A twin study of the neuropsychological consequences of stimulant abuse. Archives of General Psychiatry, 60(3), 303–310.PubMedCrossRef

Tozzi, V., Balestra, P., Bellagamba, R., Corpolongo, A., Salvatori, M. F., Visco-Comandini, U., et al. (2007). Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors. Journal of Acquired Immune Deficiency Syndrome, 45(2), 174–182.CrossRef

Tucker, J. S., Orlando, M., Burnam, M. A., Sherbourne, C., Kung, F.-Y., & Gifford, A. L. (2004). Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychology, 23(4), 363–370.PubMedCrossRef

Verdejo-Garcia, A., & Perez-Garcia, M. (2007). Profile of executive deficits in cocaine and heroin polysubstance users: Common and differential effects on separate executive components. Psychopharmacology, 190(4), 517–530.PubMedCrossRef

Volkow, N. D., Fowler, J. S., Wang, G. J., & Swanson, J. M. (2004). Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Molecular Psychiatry, 9(6), 557–569.PubMedCrossRef

Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDS, 16(12), 599–608.PubMedCrossRef

Waldrop-Valverde, D., Jones, D. L., Jayaweera, D., Gonzalez, P., Romero, J., & Ownby, R. L. (2009a). Gender differences in medication management capacity in HIV infection: The role of health literacy and numeracy. AIDS and Behavior, 13(1), 46–52.PubMedCrossRef

Waldrop-Valverde, D., Osborn, C. Y., Rodriguez, A., Rothman, R. L., Kumar, M., & Jones, D. L. (2009). Numeracy skills explain racial differences in HIV medication management. AIDS and Behavior, Epub ahead of print (Aug 6), 1–7.

Webber, M. P., Schoenbaum, E. E., Gourevitch, M. N., Buono, D., & Klein, R. S. (1999). A prospective study of HIV disease progression in female and male drug users. AIDS, 13(2), 257–262.PubMedCrossRef

Titel: Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence
Auteurs: Christina S. Meade
Nina A. Conn
Linda M. Skalski
Steven A. Safren
Publicatiedatum: 01-04-2011
Uitgeverij: Springer US
Gepubliceerd in: Journal of Behavioral Medicine / Uitgave 2/2011
Print ISSN: 0160-7715
Elektronisch ISSN: 1573-3521
DOI: https://doi.org/10.1007/s10865-010-9293-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2011

Somatic items in the assessment of depressive symptoms in pediatric patients with diabetes

A randomized clinical trial of a coping improvement group intervention for HIV-infected older adults

Health behavior modification after electron beam computed tomography and physician consultation

Short sleep mediates the association between long work hours and increased body mass index

Religious coping and hospital admissions among adults with sickle cell disease

Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis